C50
Conditions
Interventions
Group 1: Retrospective analysis cancer registry data of cases with early BC from the diagnosis years 2015-2022 (observational study)
Sponsors
Novartis
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: - ICD-10 C50 - Diagnosis years: 2015-2023 - Place of residence in the federal state of the requested registry ("population-based cases") at the time of diagnosis
Exclusion criteria
Exclusion criteria: - Cancer case is known to the registry exclusively on the basis of - a death certificate (DCO case) - a pathology report - a progress report - a report on the tumor conference - a combination of the aforementioned reporting types - Previous tumor diagnosis up to 5 years before breast cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) invasive disease-free survival (iDFS) and metastasis recurrence-free survival (DRFS) from the date of initiation of endocrine therapy, overall and stratified by stage, nodal status and menopausal status | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Description of sociodemographic and clinical characteristics of study participants at the time of initial diagnosis and/or initiation of endocrine therapy - overall and stratified by disease recurrence or non-recurrence during follow-up 2) Description of treatment patterns - overall and stratified by disease recurrence or non-recurrence during follow-up | — |
Countries
Germany
Contacts
Public ContactAnnika Waldmann
Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie
Outcome results
None listed